The Race to Commercialize the World’s Most Powerful Psychedelic | WSJ

5-MeO-DMT represents a promising frontier in psychedelic-assisted mental health treatment due to its rapid onset and profound effects. Currently, patients often travel to unregulated international clinics to use this substance for conditions like treatment-resistant depression and PTSD, where conventional therapies have failed. Its extreme potency and short duration make it a target for commercialization, with several biotech companies actively developing synthetic analogs and conducting clinical trials to secure medical approval. Regulatory support is increasing, as exemplified by the FDA granting breakthrough therapy designation to development programs for 5-MeO-DMT analogs. Industry leaders aim to standardize this substance as a controlled clinical intervention, mirroring the therapeutic model established by existing treatments like ketamine, while researchers investigate its unique role in modulating serotonin receptors to improve clinical outcomes.